bioAffinity Technologies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

April 02, 2025

bioAffinity Technologies (NASDAQ:BIAF) Full Year 2024 Results

Key Financial Results

Revenue: US$9.36m (up 270% from FY 2023).
Net loss: US$9.04m (loss widened by 14% from FY 2023).
US$0.75 loss per share.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

earnings-and-revenue-growth — NasdaqCM:BIAF Earnings and Revenue Growth April 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

bioAffinity Technologies EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 8.5%.

Looking ahead, revenue is expected to decline by 14% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.

Performance of the American Biotechs industry.

The company's shares are up 278% from a week ago.

Risk Analysis

Before you take the next step you should know about the 6 warning signs for bioAffinity Technologies (5 can't be ignored!) that we have uncovered.

If you're looking to trade bioAffinity Technologies, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.